HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

LY2940680

a smoothened receptor antagonist with antineoplastic activity; structure in first source

Also Known As:

taledegib

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridazines: 11
    - Phthalazines: 7
      - LY2940680: 2

Experts

1.	Andre, Valerie: 1 article (01/2018)
2.	Bendell, Johanna: 1 article (01/2018)
3.	Brail, Les: 1 article (01/2018)
4.	Ho, Alan: 1 article (01/2018)
5.	Infante, Jeffrey: 1 article (01/2018)
6.	Kudchadkar, Ragini: 1 article (01/2018)
7.	Migden, Michael: 1 article (01/2018)
8.	Pitou, Celine: 1 article (01/2018)
9.	Tiu, Ramon V: 1 article (01/2018)
10.	Tucker, Trevor: 1 article (01/2018)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2018 - "Purpose: The purpose of this study was to determine a recommended phase II dose and schedule of LY2940680 (taladegib) for safe administration to patients with locally advanced/metastatic cancer.Experimental" 01/01/2018 - ": LY2940680 treatment resulted in an acceptable safety profile in patients with advanced/metastatic cancer. " 01/01/2018 - "Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma." 02/01/2015 - "However, to date, Hh inhibitors, specifically those targeting Smoothened [such as vismodegib, BMS-833923, saridegib (IPI-926), sonidegib/erismodegib (LDE225), PF-04449913, LY2940680, LEQ 506, and TAK-441], have demonstrated good efficacy as monotherapy in patients with basal cell carcinoma and medulloblastoma, but have shown limited activity in other tumor types. "
2.	Basal Cell Carcinoma (Rodent Ulcer) 01/01/2018 - "Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma." 02/01/2015 - "However, to date, Hh inhibitors, specifically those targeting Smoothened [such as vismodegib, BMS-833923, saridegib (IPI-926), sonidegib/erismodegib (LDE225), PF-04449913, LY2940680, LEQ 506, and TAK-441], have demonstrated good efficacy as monotherapy in patients with basal cell carcinoma and medulloblastoma, but have shown limited activity in other tumor types. "
3.	Medulloblastoma 02/01/2015 - "However, to date, Hh inhibitors, specifically those targeting Smoothened [such as vismodegib, BMS-833923, saridegib (IPI-926), sonidegib/erismodegib (LDE225), PF-04449913, LY2940680, LEQ 506, and TAK-441], have demonstrated good efficacy as monotherapy in patients with basal cell carcinoma and medulloblastoma, but have shown limited activity in other tumor types. "

Related Drugs and Biologics

1.	BMS-833923
2.	sonidegib
3.	IPI-926
4.	HhAntag691
5.	glasdegib